Automated Dialysis Anemia Management: Role of the Treating Nephrologist.
作者信息
Fishbane Steven, Shah Hitesh H
机构信息
Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York.
出版信息
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1084-1085. doi: 10.2215/CJN.0000000000000541. Epub 2024 Aug 13.
Abstract
摘要
相似文献
1
Automated Dialysis Anemia Management: Role of the Treating Nephrologist.
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1084-1085. doi: 10.2215/CJN.0000000000000541. Epub 2024 Aug 13.
2
Association Between Nephrologist Ownership of Dialysis Facilities and Clinical Outcomes.
JAMA Intern Med. 2022 Dec 1;182(12):1267-1276. doi: 10.1001/jamainternmed.2022.5002.
3
Association between primary care physician-nephrologist collaboration and clinical outcomes in patients with stage 5 chronic kidney disease: a JOINT-KD cohort study.
J Nephrol. 2025 May 8. doi: 10.1007/s40620-025-02299-1.
4
Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Epub 2014 Oct 7.
5
The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: a systematic review.
Am J Nephrol. 2015;41(2):89-97. doi: 10.1159/000375541. Epub 2015 Feb 26.
6
Analysis of red blood cell lifespan and associated influencing factors in anemic dialysis patients.
Ren Fail. 2025 Dec;47(1):2529439. doi: 10.1080/0886022X.2025.2529439. Epub 2025 Jul 20.
7
Market Competition and Anemia Management in the United States Following Dialysis Payment Reform.
Med Care. 2023 Nov 1;61(11):787-795. doi: 10.1097/MLR.0000000000001924. Epub 2023 Sep 18.
8
Excess morbidity in patients starting uremia therapy without prior care by a nephrologist.
Am J Kidney Dis. 1996 Dec;28(6):841-5. doi: 10.1016/s0272-6386(96)90383-2.
9
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.
Cochrane Database Syst Rev. 2001(4):CD003266. doi: 10.1002/14651858.CD003266.
10
Effect of pre-end-stage kidney disease nephrology care on the association between neighborhood poverty and referral for kidney transplantation among patients with end-stage kidney disease.
J Clin Epidemiol. 2025 Jun 24;185:111878. doi: 10.1016/j.jclinepi.2025.111878.
本文引用的文献
1
Effects of Individualized Anemia Therapy on Hemoglobin Stability: A Randomized Controlled Pilot Trial in Patients on Hemodialysis.
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1138-1147. doi: 10.2215/CJN.0000000000000488. Epub 2024 Jun 11.
2
Artificial intelligence supported anemia control system (AISACS) to prevent anemia in maintenance hemodialysis patients.
Int J Med Sci. 2021 Feb 22;18(8):1831-1839. doi: 10.7150/ijms.53298. eCollection 2021.
3
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients.
Clin J Am Soc Nephrol. 2008 May;3(3):777-82. doi: 10.2215/CJN.04281007. Epub 2008 Mar 12.
4
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
Kidney Int. 2005 Sep;68(3):1337-43. doi: 10.1111/j.1523-1755.2005.00532.x.
5
Effect of variability in anemia management on hemoglobin outcomes in ESRD.
Am J Kidney Dis. 2003 Jan;41(1):111-24. doi: 10.1053/ajkd.2003.50030.
Zotero 插件